Sepsis kills 20 million people every year(↗), more than cancer. Many of these deaths are preventable, and we exist to change that for adults and children alike.
Multimodal hemoadsorption
Clinically validated multimodal hemoadsorption technology that simultaneously removes bacterial endotoxin and excessive cytokines directly from the bloodstream, addressing key molecular drivers of sepsis and acute inflammation
Learn more
25,000+ treatments administered
Including ~1,000 pediatric and 50 neonatal patients
Approved and in clinical use in 40+ countries worldwide
First and only pediatric-approved multimodal therapy for sepsis, septic shock and cytokine storm
CE-mark under EU MDR requirements
Up to 40% lower per-patient resource use in ICU
Adult
Efferon LPS
A CE-marked, single-use multimodal extracorporeal blood purification device used at the acute settings to treat sepsis, septic shock, cytokine storm, and endotoxemia
Pediatric
Efferon NEO
The first CE‑marked single-use multimodal extracorporeal blood purification device ever purpose‑built to treat pediatric sepsis and septic shock
Indications: Critical Care
Approved and in Clinical UsePost-Acute Inflammatory Syndromes
Coming soonOncology and Immunotherapy-Related Inflammation
Coming soonImmune-Mediated Systemic Diseases
Coming soon
“Every ten seconds, a child dies from sepsis. The biology is clear. The therapy exists. The device exists. What doesn't exist yet is the world that delivers it. And we're building the infrastructure to make it inexcusable for any hospital, in any country, to be without it.”
Clinical Data
Efferon's clinical evidence spans multicenter randomized controlled trials and real-world data across 40+ countries
Clinical trials(↗)Adult Patients
Septic Shock Survival 87% vs. 60%
Multicenter LASSO RCT in adult septic shock patients. Efferon LPS significantly improved 3-day survival, resolved shock twice as fast, and was associated with a shorter ICU stay (15 vs 32 days)
Pediatric Patients
Mortality: 9% vs. 35%
LASSO NEO CT in children aged 1 month–14 years. Efferon reduced 28-day mortality fourfold and accelerated weaning from vasopressors and mechanical ventilation
Global Footprint
Headquartered in Austria, with in-house manufacturing in Latvia, and trusted by leading hospitals worldwide
- Australia — In clinical use
- Austria — Headquarters
- Bulgaria — In clinical use
- Czech Republic — In clinical use
- Slovakia — In clinical use
- Estonia — In clinical use
- Latvia — Manufacturing facility
- Germany — In clinical use
- Greece — In clinical use
- Hungary — In clinical use
- Iran — In clinical use
- Israel — In clinical use
- Italy — In clinical use
- South Africa — In clinical use
- Qatar — In clinical use
- Saudi Arabia — In clinical use
- Costa Rica — In clinical use
- Paraguay — In clinical use
- Panama — In clinical use
- Poland — In clinical use
- Moldova — In clinical use
- Romania — In clinical use
- Serbia — In clinical use
- Montenegro — In clinical use
- Bosnia and Herzegovina — In clinical use
- North Macedonia — In clinical use
- Cyprus — In clinical use
- Slovenia — In clinical use
- Croatia — In clinical use
- Turkey — In clinical use
- Vietnam — In clinical use
- United Kingdom — In clinical use
- Ireland — In clinical use
- Spain — In clinical use
- Thailand — In clinical use
- Armenia — In clinical use
- Georgia — In clinical use
- Kazakhstan — In clinical use
- Uzbekistan — In clinical use
- Russia — In clinical use
- Lithuania — Registration in progress
- India — Registration in progress
- Egypt — Registration in progress
- United Arab Emirates — Registration in progress
- Kuwait — Registration in progress
- Morocco — Registration in progress
- Libya — Registration in progress
- Oman — Registration in progress
- Bahrain — Registration in progress
- Colombia — Registration in progress
- United States — Coming soon
Efferon is open to U.S. partnerships advancing extracorporeal blood purification as a standard of care in critical illness and beyond
Contact us to request our pitch deck and discuss potential collaboration